Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II dose optimization and expansion study of the combination of bempegaldesleukin (bempeg) plus Opdivo (nivolumab) in first-line non-small-cell lung cancer

Next Previous
Search
Trial Profile

A Phase I/II dose optimization and expansion study of the combination of bempegaldesleukin (bempeg) plus Opdivo (nivolumab) in first-line non-small-cell lung cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 14 Jan 2020 New trial record
    • 10 Jan 2020 According to a Nektar Therapeutics media release, this trial is being conducted under a new strategic collaboration between the company and Bristol-Myers Squibb. This study will be independently conducted and funded by Bristol-Myers Squibb.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top